Securities Registration: Employee Benefit Plan (s-8)
August 26 2019 - 4:12PM
Edgar (US Regulatory)
As filed with the Securities and Exchange
Commission on August 26, 2019
Registration No. 333-
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
CYTOSORBENTS CORPORATION
(Exact name of Registrant as specified in
its charter)
Delaware
(State or other jurisdiction
of incorporation or organization)
7 Deer
Park Drive, Suite K
Monmouth Junction, New Jersey
(Address of principal executive offices)
|
98-0373793
(I.R.S. Employer
Identification No.)
08852
(Zip Code)
|
AMENDED AND RESTATED CYTOSORBENTS CORPORATION
2014 LONG-TERM INCENTIVE PLAN
(Full title of the plan)
Phillip Chan, MD
President and Chief Executive Officer
CytoSorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction, New Jersey 08852
(732) 329-8885
|
David C. Schwartz, Esq.
Morgan, Lewis & Bockius LLP
502 Carnegie Center
Princeton, New Jersey 08540
(609) 919-6600
|
(Name, address, telephone number,
including area code, of agent for service)
|
(With copies to)
|
Indicate by check mark whether the registrant is
a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
|
¨
|
|
|
Accelerated filer
|
x
|
Non-accelerated filer
|
¨
|
|
Smaller reporting company
|
x
|
|
|
Emerging growth company
|
¨
|
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
CALCULATION OF REGISTRATION FEE
Title of securities to be registered
|
|
Amount
to be
registered(1)
|
|
|
Proposed
maximum
offering price
per share(2)
|
|
|
Proposed
maximum
aggregate
offering price(2)
|
|
|
Amount of
registration fee
|
|
Common Stock, $0.001 par
value per share
|
|
|
6,000,000
|
|
|
$
|
4.91
|
|
|
$
|
29,460,000
|
|
|
$
|
3,575
|
|
|
(1)
|
An aggregate of 13,400,000 shares of the Registrant’s Common Stock, par value $0.001 per
share (the “Common Stock”) may be offered or issued pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive
Plan, as amended and restated, 7,400,000 shares of which were previously registered on Form S-8, and 6,000,000 shares of which
are registered on this Form S-8. In addition, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities
Act”), this Registration Statement also covers an indeterminate number of shares of Common Stock, which may be offered or
issued to prevent dilution resulting from adjustments as a result of stock dividends, stock splits, reverse stock splits, recapitalizations,
reclassifications, mergers, split-ups, reorganizations, consolidations and other capital adjustments.
|
|
(2)
|
Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) and
(h). The proposed maximum offering price per share, proposed maximum aggregate offering price and the amount of the registration
fee are based on the average of the high and low prices of Common Stock as reported on the Nasdaq Capital Market on August 22,
2019. Pursuant to General Instruction E of Form S-8, the registration fee is calculated with respect to the additional securities
registered on this Form S-8 only.
|
INCORPORATION BY REFERENCE
In accordance with General Instruction E
to Form S-8, the contents of the Registration Statements filed by CytoSorbents Corporation (the “Registrant”) with
the Securities and Exchange Commission (the “Commission”) (File Nos. 333-203244 and 333-220630), with respect to securities
offered pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan are hereby incorporated by
reference.
The following documents previously filed
by the Registrant with the Commission are incorporated by reference into this Registration Statement:
|
(4)
|
The Registrant’s Current Reports on Form 8-K filed with the Commission on January
24, 2019, February 5,
2019, March 7, 2019, June
4, 2019, June 5, 2019
(with respect to item 5.07 only), June
13, 2019, July 9, 2019, July
26, 2019, August 5, 2019 and August 5, 2019 (provided that any portions of such reports that are deemed furnished and
not filed
pursuant to
instructions to Form 8-K shall not be incorporated by
reference into this Registration Statement); and
|
|
(5)
|
The description of Common Stock set forth in the Registrant’s Registration Statement on Form 8-A12B filed with the Commission
on December 17, 2014 pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
including any amendment or report filed for the purpose of updating such description.
|
To the extent that any information contained
in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information
or exhibit is specifically not incorporated by reference.
In addition, all documents
that the Registrant files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date
of this Registration Statement (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant
to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), but prior to the filing
of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or which
deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement
and to be a part hereof from the date of filing such documents.
For purposes of this
Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently
filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement
in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this Registration Statement.
EXHIBITS
SIGNATURES
Pursuant to the requirements of
the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in Monmouth Junction, New Jersey, August 26, 2019.
|
CYTOSORBENTS CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ Dr. Phillip P. Chan
|
|
Name:
|
Dr. Phillip P. Chan
|
|
Title:
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
We, the undersigned
officers and directors of CytoSorbents Corporation, hereby severally constitute and appoint Phillip P. Chan and Kathleen P. Bloch,
our true and lawful attorneys, with full power to each of them singly, to sign for us and in our names in the capacities indicated
below, the Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said Registration Statement,
and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable CytoSorbents
Corporation to comply with the provisions of the Securities Act of 1933 as amended, and all requirements of the Securities and
Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them,
to said Registration Statement and any and all amendments thereto.
Pursuant to the requirements
of the Securities Act of 1933, as amended this Registration Statement has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Dr. Phillip P. Chan
Dr. Philip P. Chan
|
|
President and Chief Executive Officer (Principal Executive Officer) and Director
|
|
August 26, 2019
|
|
|
|
|
|
/s/ Kathleen P Bloch
Kathleen P. Bloch
|
|
Chief Financial Officer (Principal Financial and Accounting Officer)
|
|
August 26, 2019
|
|
|
|
|
|
/s/ Al W. Kraus
|
|
Director
|
|
August 26, 2019
|
Al W. Kraus
|
|
|
|
|
|
|
|
|
|
/s/ Alan D. Sobel
|
|
Director
|
|
August 26, 2019
|
Alan D. Sobel
|
|
|
|
|
|
|
|
|
|
/s/ Edward R. Jones
|
|
Director
|
|
August 26, 2019
|
Edward R. Jones
|
|
|
|
|
|
|
|
|
|
/s/ Michael G. Bator
|
|
Director
|
|
August 26, 2019
|
Michael G. Bator
|
|
|
|
|
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Sep 2023 to Sep 2024